60 related articles for article (PubMed ID: 28285371)
1. The ratio of intratumoral CD15
Watanabe J; Kimura T; Saze Z; Sato N; Kofunato Y; Ishigame T; Okada R; Kenjo A; Kono K; Marubashi S
Cancer Rep (Hoboken); 2024 Jun; 7(6):e2099. PubMed ID: 38837676
[TBL] [Abstract][Full Text] [Related]
2. Combined Neutrophil-to-Lymphocyte Ratio Score Is Associated With Chemotherapeutic Response and Predicts Prognosis in Patients With Advanced Pancreatic Cancer.
Okabe H; Masuda T; Tomita M; Ono A; Ogawa D; Kuroda D; Kuroki H; Hirota M; Hibi T; Baba H; Sugita H
Anticancer Res; 2024 Apr; 44(4):1575-1582. PubMed ID: 38537961
[TBL] [Abstract][Full Text] [Related]
3. Recurring Pancreatic Neuroendocrine Tumor: Timing and Pattern of Recurrence and Current Treatment.
Pulvirenti A; Javed AA; Michelakos T; Sekigami Y; Zheng J; Kalvin HL; McIntyre CA; Nebbia M; Chou JF; Gonen M; Raj N; Reidy-Lagunes DL; Zureikat AH; Ferrone CR; He J; Wei AC;
Ann Surg; 2023 Nov; 278(5):e1063-e1067. PubMed ID: 37796750
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors.
Luo G; Liu C; Cheng H; Jin K; Guo M; Lu Y; Long J; Xu J; Ni Q; Chen J; Yu X
Oncol Lett; 2017 Apr; 13(4):2454-2458. PubMed ID: 28454419
[TBL] [Abstract][Full Text] [Related]
5. Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors.
Okuyama H; Ikeda M; Takahashi H; Ohno I; Hashimoto Y; Mitsunaga S; Sakamoto Y; Kondo S; Morizane C; Ueno H; Kobayashi T; Arai Y; Okusaka T
Oncology; 2017; 92(6):353-359. PubMed ID: 28329738
[TBL] [Abstract][Full Text] [Related]
6. The Predicting Role of the Neutrophil-to-Lymphocyte Ratio for the Tumor Grade and Prognosis in Pancreatic Neuroendocrine Tumors.
Oh D; Pyo JS; Chung KH; Son BK
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328291
[TBL] [Abstract][Full Text] [Related]
7. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
Giannetta E; La Salvia A; Rizza L; Muscogiuri G; Campione S; Pozza C; Colao AAL; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():672499. PubMed ID: 34367064
[TBL] [Abstract][Full Text] [Related]
8. Involvement of Neutrophils in Metastatic Evolution of Pancreatic Neuroendocrine Tumors.
Debien V; Davidson G; Baltzinger P; Kurtz JE; Séverac F; Imperiale A; Pessaux P; Addeo P; Bachellier P; Su X; Davidson I; Chenard MP; Goichot B; Malouf GG
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199561
[TBL] [Abstract][Full Text] [Related]
9. Serum Inflammation-based Scores in Endocrine Tumors.
Marques P; de Vries F; Dekkers OM; Korbonits M; Biermasz NR; Pereira AM
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3796-e3819. PubMed ID: 33837783
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.
Bannaga A; Arasaradnam RP
World J Gastroenterol; 2020 Sep; 26(33):5022-5049. PubMed ID: 32952347
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
Grenader T; Pavel ME; Ruszniewski PB; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Truong Thanh XM; Caplin ME;
Anticancer Drugs; 2020 Mar; 31(3):216-222. PubMed ID: 31977567
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.
Lee L; Ito T; Jensen RT
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1029-1050. PubMed ID: 31738624
[No Abstract] [Full Text] [Related]
13. Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Zhou Y; Li D; Lin Y; Yu M; Lu X; Jian Z; Na N; Hou B
Onco Targets Ther; 2018; 11():2489-2496. PubMed ID: 29760558
[TBL] [Abstract][Full Text] [Related]
14. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors.
Zhou B; Deng J; Chen L; Zheng S
Sci Rep; 2017 Dec; 7(1):17506. PubMed ID: 29235538
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors.
Arima K; Okabe H; Hashimoto D; Chikamoto A; Nitta H; Higashi T; Kaida T; Yamamura K; Kitano Y; Komohara Y; Yamashita YI; Beppu T; Takeya M; Baba H
Int J Clin Oncol; 2017 Aug; 22(4):734-739. PubMed ID: 28285371
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.
Zhou B; Zhan C; Xiang J; Ding Y; Yan S
BMC Endocr Disord; 2019 Nov; 19(1):123. PubMed ID: 31718651
[TBL] [Abstract][Full Text] [Related]
18. Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG).
Panni RZ; Lopez-Aguiar AG; Liu J; Poultsides GA; Rocha FG; Hawkins WG; Strasberg SM; Trikalinos NA; Maithel S; Fields RC;
J Surg Oncol; 2019 Sep; 120(4):632-638. PubMed ID: 31339198
[TBL] [Abstract][Full Text] [Related]
19. The Role of Surgery for Pancreatic Neuroendocrine Tumors.
Ziogas IA; Schmitz R; Moris D; Vatsaas CJ
Anticancer Res; 2022 Feb; 42(2):629-639. PubMed ID: 35093860
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
